newsfilter
← Latest News
GlobeNewswire·

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

PRME
  • Prime Medicine, Inc. appointed Svetlana Makhni as Chief Financial Officer on April 16, 2026.
  • Ms. Makhni will oversee financial operations, strategy, investor relations, financial planning, analysis, & corporate development.
  • Her appointment aims to support Prime Medicine as it prepares to enter clinical trials for Wilson Disease & Alpha-1 Antitrypsin Deficiency.
  • Ms. Makhni brings over 20 years of experience, including prior CFO roles at Marengo Therapeutics, Escient Pharmaceuticals, & Bierman ABA.
  • She previously held investment banking positions at BMO Capital Markets, Goldman Sachs, Westbrook Partners, & The Blackstone Group.
  • Ms. Makhni holds an M.B.A. from Harvard Business School & a B.S. from the Wharton School of the University of Pennsylvania.
  • Prime Medicine utilizes its proprietary Prime Editing platform to develop one-time curative genetic therapies for liver, lung, & immunology/oncology indications.
  • The company's pipeline currently targets high-value programs in Wilson Disease & Alpha-1 Antitrypsin Deficiency with plans to expand into thousands of potential indications.
  • Forward-looking statements regarding the company's strategy, product development, & financial performance are included in the press release.